HCG · NSE
Healthcare Global Enterprises Limited
₹624.95
+1.63% (+₹10.05)
Prev. close
₹614.9
Volume
81,314
Delivery %
51.9%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
3 analyst stances · last 90 days · one per analyst
Trackable
3 · 3 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Axis Direct rates Healthcare Global Enterprises as a buy with a target of ₹820, driven by solid earnings growth and expa…” | ETMarkets AnalysisETMarkets.com | Healthcare Global Enterprises | PENDING | |
| “Bullish on Healthcare Global Enterprises with a target price of ₹820, indicating an upside of 39.2% from its current mar…” | PL Capital AnalysisPL Capital | Healthcare Global Enterprises Ltd | PENDING | |
| “Bullish on Healthcare Global Enterprises with a target price of ₹820, forecasting a 23% upside from current levels. The …” | Axis Securities AnalysisAxis Securities | Healthcare Global Enterprises | PENDING | |
| “Axis Securities forecasts an upside potential of 12.2% for Healthcare Global Enterprises, with a target price of Rs 820.…” | Axis Securities AnalysisAxis Securities | Healthcare Global Enterprises | PENDING | |
| “Recommends buying HealthCare Global Enterprises Ltd (HCG) at around ₹651.55, targeting ₹700 with a stop loss at ₹630. HC…” | Sumeet BagadiaChoice Equity Broking | HealthCare Global Enterprises Ltd | NOT TRIGGERED | |
| “Axis Securities recommends buying Healthcare Global Enterprises (HCG) shares for a short-term gain, setting a target pri…” | Axis Securities AnalysisAxis Securities | Healthcare Global Enterprises Ltd | HIT | |
| “Bullish on Healthcare Global Enterprises, recommending a buy at ₹562.45 with a target of ₹600 and a stop loss at ₹540. T…” | Sumeet BagadiaChoice Equity Broking | Healthcare Global Enterprises Ltd | HIT | |
| “Recommends buying Healthcare Global Enterprises at ₹574, targeting ₹615, with a stop loss at ₹555. This is presented as …” | Sumeet BagadiaChoice Equity Broking | Healthcare Global Enterprises Ltd | MISS | |
| “Recommends buying HealthCare Global Enterprises Ltd in the near term, targeting ₹578 and ₹625, with a stop-loss at ₹481.…” | Vinay RajaniHDFC Securities | HealthCare Global Enterprises Ltd | HIT | |
| “Bullish on HealthCare Global Enterprises Ltd. (HCG), recommending a buy at ₹542.1 with a target of ₹580 and a stop loss …” | Sumeet BagadiaChoice Equity Broking | HealthCare Global Enterprises Ltd. | HIT | |
| “Recommends buying Healthcare Global Enterprises Ltd in the near term, targeting Rs. 578-625 with a stop-loss at Rs. 481.…” | Vinay RajaniHDFC Securities | Healthcare Global Enterprises Ltd | HIT | |
| “Axis Securities recommends buying Healthcare Global Enterprises with a target price of Rs 575. The company is expected t…” | Axis Securities AnalysisAxis Securities | Healthcare Global Enterprises Ltd | PENDING | |
| “Prabhudas Lilladher recommends buying Healthcare Global Enterprises with a target price of ₹555. The call is based on th…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Healthcare Global Enterprises Limited | HIT | |
| “Recommends buying Healthcare Global Enterprises at ₹488.50, targeting ₹523, with a stop loss at ₹471. This is a stock-sp…” | Sumeet BagadiaChoice Equity Broking | Healthcare Global Enterprises Ltd | PENDING | |
| “Recommends buying Healthcare Global Enterprises with a target price of ₹535. The call is based on the company's strong f…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Healthcare Global Enterprises Limited | HIT |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “PL Capital is bullish on Healthcare Global Enterprises, projecting a 39.2% upside from current levels. The stock is incl…” | PL Capital AnalysisPL Capital | Healthcare Global Enterprises | — |
Fundamentals
About Healthcare Global Enterprises Limited
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services, including patient care, psychological support, nutrition, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, yoga therapy, bone marrow transplant, organ-specific oncology, radiation oncology, liver transplantation, radiology and imaging, clinical laboratory, day care chemotherapy center, home health care, preventive and psycho oncology, translational and nuclear medicine, oncodermatology, paediatric and gynaecologic oncology, anaesthesiology, and orthopaedic oncology. In addition, the company offers gastrointestinal and thoracic oncology, breast surgical oncology, and pain and palliative services. Further, it operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care; and provides oncology diagnostics services, including biomarkers, translational research, and clinical research services under the Triesta Sciences brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Manish Mattoo
Headquarters
Bengaluru
Employees
6,761
Website
hcgoncology.comExchange
View on NSE ↗Key stats
Market cap
₹9,199.26 Cr
P/E ratio (TTM)
405.4
Dividend yield
0.00%
EPS (TTM)
₹1.52
Beta (1Y · daily vs NIFTY 50)
0.69
Beta (5Y · monthly vs NIFTY 50)
0.38
Shares float
5.95 Cr
EPS · quarter ended Jun 2026
₹0.92
Financial Performance
01 · Financials
EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,013.44 Cr | ₹1,397.79 Cr | ₹1,694.44 Cr | ₹1,912.12 Cr | ₹2,222.85 Cr | ₹2,545.41 Cr | |
EBITDA | ₹50.09 Cr | ₹345.26 Cr | ₹302.75 Cr | ₹350.43 Cr | — | — |
| ₹-193.46 Cr | ₹53.73 Cr | ₹29.34 Cr | ₹48.14 Cr | ₹44.41 Cr | ₹13.76 Cr | |
Diluted EPS | ₹-17.02 | ₹3.97 | ₹2.1 | ₹3.43 | ₹3.14 | ₹0.96 |
EBITDA has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹50.09 Cr while the annual report gives ₹143.54 Cr (186.6% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹179.16 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,031.00 Cr | ₹2,218.00 Cr | ₹2,311.00 Cr | ₹2,701.00 Cr | ₹3,540.00 Cr | ₹3,920.00 Cr | |
| — | ₹914.68 Cr | ₹901.20 Cr | ₹1,274.36 Cr | ₹1,837.22 Cr | ₹1,735.35 Cr | |
Stockholders' equity | ₹697.00 Cr | ₹870.00 Cr | ₹860.00 Cr | ₹825.00 Cr | ₹922.00 Cr | ₹1,332.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹121.00 Cr | ₹220.00 Cr | ₹252.00 Cr | ₹285.00 Cr | ₹317.00 Cr | ₹347.00 Cr | |
Investing cash flow | ₹-171.10 Cr | ₹124.58 Cr | ₹-133.02 Cr | ₹-225.73 Cr | ₹-487.75 Cr | ₹-177.47 Cr |
| ₹112.00 Cr | ₹-155.00 Cr | ₹-140.00 Cr | ₹-64.00 Cr | ₹-42.00 Cr | ₹241.00 Cr | |
Capital expenditure | ₹-35.00 Cr | ₹-71.00 Cr | ₹-133.00 Cr | ₹-186.00 Cr | ₹-209.00 Cr | ₹-292.00 Cr |
End cash position | ₹2.86 Cr | ₹192.69 Cr | ₹171.18 Cr | ₹166.01 Cr | ₹-47.05 Cr | ₹363.23 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26–Jun 26(3Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.41% | 71.02% | 71.44% | 71.43% | 71.42% | 71.39% | 71.38% | 71.37% | 71.35% | 71.30% | 71.29% | 71.28% | 71.25% | 71.23% | 71.22% | 62.46% | 63.78% | 63.77% | 64.21% |
| Public | 31.60% | 28.99% | 28.56% | 28.57% | 28.58% | 28.61% | 28.62% | 28.63% | 28.65% | 28.70% | 28.71% | 28.72% | 28.75% | 28.77% | 28.78% | 37.54% | 36.22% | 36.23% | 35.79% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Healthcare Global Enterprises Limited | ₹9,316.46 Cr | ₹621.35 | 402.6 | 6.99 | 1.0% | 1.30 | +14.6% | -18.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Why HCG Fell Even As Sales Rose
HealthCare Global Enterprises' shares dropped to about ₹600, a 20.5% loss over the past year despite revenue rising to ₹7.34 billion in Q2 2027. The decline reflects shrinking net margins, which fell to 0.7% as net income dropped, challenging earlier expectations of strong margin expansion from its oncology and KKR‑backed growth plans.